Therapixel has received a second 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MammoScreen, AI-based software assisting radiologists in breast cancer screening. This new clearance expands the use of Mammoscreen to Digital Breast Tomosynthesis (3D Mammography). Therapixel is a French company specialized in the design and commercialization of AI-powered medical imaging software, with the goal of delivering pertinent information…
![](https://femtechinsider.com/wp-content/uploads/2021/11/breast-cancer-diagnostics-1-1000x658.jpg)